Lenzilumab

Tax included
Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.
MedChemExpress 
HY-P99207

Data sheet

Size
Multiple sizes
Reactivity
SARS-CoV
Application
Cancer-programmed cell death
CAS
1229575-09-0